ZYMEWORKS WKN: A3DSSN ISIN: US98985Y1082 Forum: Aktien User: Summer.76

Zymeworks, Jazz in pact over cancer antibody zanidatamab https://seekingalpha.com/news/3960469-zymeworks-jazz-pact-cancer-antibody-zanidatamab • Zymeworks (ZYME) will transfer some assets, contracts, and employees related to the development of its oncology antibody zanidatamab to Jazz Pharmaceuticals (NASDAQ:JAZZ) to speed up its development. • The two companies have inked a stock and asset purchase agreement to facilitate the arrangement. • Jazz (JAZZ) will be solely responsible for all development and commercial activities of zanidatamab in the US, Europe, and Japan, and other areas except for the Asia/Pacific region. Zymeworks is also partnered with Beigene (BGNE) on the asset. The Chinese pharma has rights to zanidatamab in the Asia/Pacific region. • The deal is expected to close in May. • The two companies first signed a collaboration agreement on zanidatamab in October 2022. Zymeworks (ZYME) received a $50M upfront payment and is eligible for up to $1.76B total including potential milestone payments.

https://www.globenewswire.com/news-release/2023/04/18/2649554/0/en/Zymeworks-Presents-New-Data-from-Multiple-Preclinical-and-Clinical-Development-Programs-at-the-2023-American-Association-for-Cancer-Research-Annual-Meeting.html

Zymeworks: Exciting Short Squeeze Candidate With Large Cash Holdings https://seekingalpha.com/article/4593080-zymeworks-exciting-short-squeeze-candidate-with-large-cash-holdings Summary • Zymeworks has an enterprise value approaching zero, as milestone drug development payments were paid to the company in 2022. • A significant pipeline, with partners helping to finance drug trials, is worthy of consideration. • Numerous short sellers may be trapped on overly aggressive downside bets. Short covering could spike the share quote later this year. • My momentum quant-sort formulas are now suggesting ZYME is primed to rise in the coming months. ...

https://seekingalpha.com/news/3949515-zymeworks--buy-at-wells-fargo-royalty-streams-future-milestones Zymeworks a buy at Wells Fargo on royalty streams, future milestones • Wells Fargo said that Zymeworks (NASDAQ:ZYME) is a buy citing the biotech's potential royalty streams and milestones from its lead oncology candidate. • The firm has a $12 price target (~41% upside based on Monday's close). • Derek Archila wrote that royalty streams from Jazz Pharmaceuticals (JAZZ) "offer nice floor value for the stock." Those streams are related to the bispecific antibody zanidatamab in late-stage development for various cancers. • The analyst gives a 75% probability of success for zanidatamab in biliary tract cancers with royalties coming in beginning in 2025. • Although late-stage data on zanidatamab for gastric esophageal adenocarcinoma isn't expected from Jazz (JAZZ) until H2 2024, Archila is optimistic and added that the biologics' royalty and milestone streams could add as much as $10/share. • Zymeworks (ZYME) is also partnered with BeiGene (BGNE) on zanidatamab.

https://kalkinemedia.com/us/amp/business-news/pharma/brief-zymeworks-inc-on-march-17-zymeworks-bc-inc-a-unit-of-co-and-daiichi-sankyo-entered-into-a-termination-and-license-agreement-dated-sept-26-2016

Zymeworks Q4 Adj. EPS $4.71 Misses $4.84 Estimate, Sales $402.49M Beat $371.30M Estimate https://www.benzinga.com/news/earnings/23/03/31246389/zymeworks-q4-eps-4-65-misses-4-84-estimate-sales-402-49m-beat-371-30m-estimate

Zymeworks Reports Fourth Quarter and Full Year 2022 Financial Results https://www.businesswire.com/news/home/20230307005535/en/Zymeworks-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results

https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-and-zymeworks-announce-84-overall-survival-at-18-months-from-phase-2-trial-evaluating-zanidatamab-in-her2-expressing-metastatic-gastroesophageal-adenocarcinoma-301725785.html

🎈

https://www.conferencecalltranscripts.org/summary/?id=11707563 Major owner of Zymeworks Inc. just picked up 985,100 shares

Nette Bewegung nachbörslich....

Insider Buys Shares Worth $8M https://www.tipranks.com/news/zymeworks-nasdaqzyme-stock-insider-buys-shares-worth-8m

Zymeworks: Good Data, Lots Of Cash, Stagnant Stock https://seekingalpha.com/article/4569409-zymeworks-good-data-lots-of-cash-stagnant-stock Summary • Last month, ZYME presented strong data in HER2+ BTC. • Its Jazz collaboration has given it access to a lot of funds. • The stock is still stagnant, probably because the market feels ZYME lacks growth prospects. ...

Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2023 https://www.businesswire.com/news/home/20230104005869/en/Zymeworks-Provides-Corporate-Update-on-Key-Strategic-Priorities-and-Outlook-for-2023 • Provides updated key priorities and focus on enterprise value framework • Closing of Jazz Pharmaceuticals (Jazz) collaboration in fourth quarter completes financial transformation initiatives originally planned for 2022 • Announces additional financial guidance on expected cash runway; provides unaudited cash and cash resources balance as of December 31, 2022 • Announces recommended Phase 2 dose (RP2D) for zanidatamab zovodotin (ZW49) ... Based on current operating plans, we expect to have cash resources to fund research and development programs, as well as operations, through at least the end of 2026, and potentially beyond. ...

https://www.sec.gov/Archives/edgar/data/1937653/000092189523000006/0000921895-23-000006-index.htm

https://newsfilter.io/a/26ed65126e6bf06a7bb0f61edec86e59 Form SC 13G (statement of acquisition of beneficial ownership by individuals) filed with the SEC